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Abstract
Background: Diagnosis of Epstein–Barr virus (EBV) infection is routinely conducted by clinical laboratories, especially to
diagnose infectious mononucleosis. At an estimated general population incidence of 1:200, this represents a potentially
significant testing burden. We evaluated the reliability of the Siemens Novagnost® and Enzygnost® EBV microtiter
assays measuring VCA IgM and IgG, and EBNA-1 IgG for clinical diagnosis of EBV-related infectious mononucleosis.
Methods: Remnant sera from 537 patients tested for EBV infection were used to compare the Siemens assays to each
other and to the Merifluor assay. The Siemens assays are qualitative/semiquantitative, automatable enzyme
immunoassays. The Merifluor assays are manual, qualitative indirect immunofluorescent assays. Testing was conducted
on the Siemens and Merifluor assays in parallel. All assays were conducted and interpreted according to each
manufacturer’s specifications. Agreement of serostatus between each of the three assays was assessed. Discrepant
results were resolved using a third method (Mikrogen recomLine).
Results: Final EBV serostatus indicated 2.9% of the population had an acute infection, 89.6% had a past infection, and
7.5% were EBV naive. All three assays demonstrated 100% agreement with acute infection. Agreement with past-
infection serostatus was 99.1% for Enzygnost, between 86% and 98.8% for Novagnost, and 98.1% for Merifluor.
Seronegative agreement was 100% for Enzygnost, 89.7% for Novagnost, and 92.3% for Merifluor.
Conclusions: The Siemens Enzygnost and Novagnost EBV microtiter assays are suitable for clinical rule-in of acute EBV
infection and for identifying EBV-naive individuals. Both assays also adequately identify remote EBV infections. Because these
assays can be automated, they can improve speed and efficiency of EBV testing, especially in high-volume laboratories.
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Background
Epstein–Barr virus (EBV) is a ubiquitous pathogen
endemic in most populations. According to the World
Health Organization (WHO), approximately 95% of the
adult population is infected, and in developed nations
approximately 50% to 70% of exposures occur in adoles-
cents or young adults. The majority of these infections
are either asymptomatic or manifest with only minor upper
respiratory symptoms, but approximately 30% of primary
infections in adolescence or beyond present as infectious
mononucleosis (IM). In the U.S., overall incidence of IM is
estimated at 1:200, while incidence in 10- to 19-year-old
adolescents is greater, at 6 to 8 cases per 1000 individuals
per year [1-3].
Although EBV-related IM is typically a fairly benign
disease, early and accurate diagnosis is valuable as it is
highly communicable and can spread quickly in popula-
tions with a high density of young adults (such as among
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university students and military personnel). In rare
instances however, sequelae of EBV-related IM can pose
serious health risks, such as trauma-induced or spontan-
eous splenic rupture, fulminant helpatitis, or autoimmune
hemolytic anemia. Furthermore, a great diversity of viral,
bacterial, parasitic, and immunologic diseases can mimic
IM symptoms, especially in early infection [4]. Thus, test-
ing to confirm or rule out EBV infection has unquestioned
diagnostic value and is standard clinical practice when
classic symptoms (pharyngitis, fatique, fever, and
adenopathy) have persisted for 2 or more weeks, espe-
cially in individuals between the ages of 10 and
30 years, and pregnant women [3]. Classically, the
Paul–Bunnel heterophile agglutination test has been
used for laboratory confirmation of acute EBV infec-
tion but several limitations exist. Sensitivity can be
lower than desirable in early infection, and specificity
when testing young children can be poor [3,5]. Specifi-
city can also be affected by cross-reactivity with other
viral and nonviral pathogens and some immunological
markers [6]. Additionally, natural loss of heterophile
antibodies impacts assessment of susceptibility or deter-
mination of other serostatus later in infection. Because
heterophile agglutination assays must be conducted
manually, they are not conducive to large-volume testing
in midsize and large laboratories, where high throughput
is required. Thus, specific serology to detect antibodies to
viral proteins is used as both an adjunct and alternative to
the heterophile test, and is most commonly directed at the
antibodies made againsts viral capsid proteins (VCA) and
Epstein–Barr nuclear antigens (EBNA).
Indirect immunofluorescence assays (IFA) using EBV-
infected lymphocytes as the binding substrate are highly
sensitive and specific for detecting serum antibodies to
viral antigens. These assays can be used to diagnose
active infections and differentiate acute from resolved
infections and are frequently considered a gold standard,
however close to 9% of results are uninterpretable [7].
IFA is a manual method which is more labor intensive
than automated or semiautomated microtiter systems. It
also requires substantial training of personnel for inter-
pretation and is not easily standardizable; thus it too is
not well suited for high-volume testing [8].
In contrast, serology for EBV-specific IgM and IgG
antibodies by ELISA-type methods provides both high
sensitivity and high specificity for acute infection [9,10],
and may offer advantages for diagnostic confirmation
earlier in the disease course—especially in those cases
where symptoms are persistent but heterophile anti-
bodies are not detectable. It can distinguish between
acute and remote (past) infection, especially after hetero-
phile antibodies have peaked or disappeared [6]. Further-
more, depending on the quality of the method, the
serological profile can usually be determined reliably
following a single blood draw. The ability to differentiate
between susceptibility and acute vs. previous infection
on the basis of a single blood draw is advantageous as it
reduces the impact on both the patient and the labora-
tory. For the high-volume laboratory in particular, this
advantage is further enhanced when semiautomated or
automated assays are used to improve laboratory
throughput.
Unfortunately, EBV serology is not always clear cut, as
unusual serological patterns may be observed in up to
10% of patients [9,11]. While the presence of VCA IgM
with or without VCA IgG typically signals acute infec-
tion, and the persistence of VCA IgG along with the
appearance of IgG to the late protein EBNA-1 indicates
past or resolving infection, unusual serological patterns
such as isolated EBNA-1 or isolated VCA IgG can con-
found interpretation. Thus, to determine their usefulness
for regular diagnostic laboratory testing, we evaluated
the serological profiles interpreted from the combined
results of the Siemens Novagnost VCA IgM, VCA IgG,
and EBNA-1 IgG assays, and the combined results of
the Enzygnost Anti-EBV/IgG and Anti-EBV/IgM II
microtiter assays to rule in, or rule out, acute EBV infec-
tion. Our goal was to show that serostatus assignment
could be achieved on the basis of a single blood sample
by comparing the agreement of the results generated by
the Siemens assays with the final empirically derived
EBV serostatus for each sample.
Methods
The serological assignments derived from combined ana-
lysis of the three Novagnost EBV enzyme immunoassays
(VCA IgM, VCA IgG, and EBNA-1 IgG) were compared
to the serological assignments derived from combined
analysis of the two Enzygnost enzyme immunoassays
(Anti-EBV IgG and Anti-EBV/IgM II). The Novagnost
and Enzygnost assays are products of Siemens Healthcare
Diagnostics GmbH (Marburg, Germany). Serological
assignments were also made using the combined analysis
of the two Merifluor EBV immunofluorescence assays
(IgG and IgM: Meridian Bioscience Europe, Nivelles,
Belgium). In total, five Siemens assays and two Merifluor
assays were used in this study.
Samples were analyzed in parallel. A final serostatus
(negative, acute, or past infection) was assigned to each
sample on the basis of the combined results of all three
assay sets, as defined by agreement between at least two
of the three test types. For example, to be serostatus-
negative, both IgM and IgG results had to be negative
according to the assignments determined by at least two
of the three methods. If results were indeterminate, a
fourth assay (recomLine EBV IgG and IgM line immuno-
assays; Mikrogen Diagnostik, Neuried, Germany) was
used as a referee method to designate serostatus.
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Following serostatus assignment for each sample, agree-
ment between the assigned status and the individual
results from the Enzygnost, Novagnost, and Merifluor
methods were compared to determine their ability to
correctly differentiate between EBV-naive status, acute
infection, and past infection on the basis of a single
blood draw.
Assay design
The Novagnost EBV VCA IgG, Novagnost EBV VCA
IgM, and Novagnost EBV EBNA-1 IgG assays are qualita-
tive/semiquantitative enzyme immunoassays (ELISAs)
conducted in microtiter strip wells. In the VCA IgG and
IgM assays, wells are coated with recombinant p18 anti-
gen; in the EBNA assay, wells are coated with recombin-
ant EBNA-1 antigen. In each assay, EBV antibodies in
patient samples create antibody–antigen complexes, after
which they are incubated with peroxidase-labeled anti–
human IgG (VCA IgG and EBNA-1 IgG assays) or IgM
(VCA IgM assay). Following subsequent washing steps,
samples are incubated further with tetramethylbenzidine
(TMB). After addition of a stop solution, color intensity is
measured at 450 nm. Absorbance, which is proportional
to the antibody level in the patient sample, may be calcu-
lated manually, although in this study, it was determined
automatically using the Siemens BEP® III analyzer. The
level of EBV antibodies in the sample is provided in
Novagnost units (U) for all three assays. According to
the manufacturer, results <8.5 U should be considered
negative and those >11.5 U, positive; while those
between 8.5 and 11.5 U fall within the gray zone. For
the purposes of this study, however, results >11.5 U
were considered positive, while all results ≤ 11.5 U
were considered negative.
Both the Enzygnost Anti-EBV/IgG and Enzygnost
Anti-EBV/IgM II assays are qualitative/semiquantitative
enzyme immunoassays (ELISAs) conducted in microtiter
strip wells coated with EBV antigens originally derived
from EBV-infected lymphoblastoid cells undergoing
active viral replication. For each assay, control wells con-
tain antigen from EBV-infected lymphoblastoid cells in
which viral synthesis has been blocked. Reactivity is
defined by the difference in absorbance (ΔA) measured
at 450 nm between the sample and control antigen
wells. If results are calculated manually, a value correc-
tion factor (CF) must be applied; in our study, how-
ever, values were determined using the BEP III
analyzer, which automatically includes the CF in its re-
sults calculation. As with the Novagnost assays, the
Enzygnost assays employ an indirect EIA format; color
intensity increases with higher serum concentrations
of EBV antibody. For the IgM assay, ΔA ≥0.120 is con-
sidered positive, while ΔA <0.120 is negative. For the
IgG assay, ΔA of 0.200 marks the upper retest limit,
while for negative samples, ΔA of <0.100 is the cutoff
value. Results are equivocal if 0.100 ≤ ΔA ≤ 0.200.
The Merifluor EBV VCA IgM and EBV VCA IgG IFA
methods are manual, qualitative indirect immunofluor-
escent assays. EBV-infected lymphocytes from Burkitt
lymphoma tumors are incubated with patient serum and
coated onto slides. After washing, cells complexed with
bound anti-VCA antibodies are incubated with either
anti–human IgM or anti–human IgG tagged with fluor-
escein. Infected cells glow light yellow to green using
fluorescence microscopy if the patient sample is positive
for the antibody being investigated. The sample is con-
sidered to be positive if approximately 10% to 20% of the
cells in each field fluoresce upon visual inspection.
The Mikrogen assays use recombinant proteins devel-
oped from the antigenic components of early antigen
(EA: p54, p138), immediate early antigen (IEA: BZLF-1,
ZEBRA), VCA (p18, p23), and EBNA-1 (p72). Antigens
are bound to nitrocellulose test strips. The IgM test strip
is coated with p23, ZEBRA, p138, and p54 antigens, and
the IgG test strip is coated with EBNA-1, p18, p23,
BZLF-1, p138, and p54 antigens. Strips blotted with each
antigen are cut into smaller strips, each of which is incu-
bated with patient serum. After washing, incubation
continues with anti–human IgG or anti–human IgM
coupled with horseradish peroxidase. Upon addition of
chromogen, a positive reaction is noted by a dark band
appearing on the test paper. The Mikrogen assays are
conducted and read manually.
Patient population and assignment of serostatus
Samples were derived from remnant sera drawn at our
laboratory (Institute of Hygiene, University of Graz)
from 537 patients who originally had been referred for
testing after clinical evaluation and history suggested
possible EBV infection or exposure. Blood samples were
collected sequentially as patients were referred. Because
this study was non-interventional and the sample sera
were originally obtained in the course of regular clinical
care and not for experimental purposes, this study
required neither patient consent nor ethics board review
per Austrian regulations as outlined in the document
“Scientific Guidance for the Conduct of Non-
interventional Studes (NIS) in Austria”. This guidance
document is issued by the Bundesamt für Sicherheit im
Gesundheitswesen (Federal Office for Health Service
Security), and can be accessed at http://www.basg.gv.at/
uploads/tx_basginfobox/L_Z61_Guidance_NIS_AT.pdf.
Statistical analysis
Although immunofluorescent methods are highly sensi-
tive, such tests, including the Merifluor test, are not con-
sidered to be definitive reference methods. All tests in
this study were therefore evaluated in terms of statistical
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agreement according to the methods outlined in the
FDA guidance document on appropriate statistical
methods used for evaluating diagnostic tests [12].
Analysis was conducted by the investigators with the
input of two biostatisticians.
Results
A total of 537 sera were available for testing using the
Siemens and Merifluor methods. Samples were assigned
a final interpretation of negative, acute infection, past
infection, or indeterminate on the basis of agreement
between results of the three assays used. Status was
assigned if results of at least two of the three methods
(Novagnost, Enzygnost, Merifluor) yielded the same in-
terpretation. If at least two of the three methods for any
serum sample did not agree or were deemed indetermin-
ate, the Mikrogen assay was used to resolve EBV status.
If no resolution could be achieved using the Mikrogen
assay, the sample was excluded from the study. Inter-
pretation algorithms for the Siemens, Merifluor, and
Mikrogen assays are presented in Tables 1, 2, and 3.
Of the available samples, results from only 518 were
ultimately included in this study. Nineteen sera could
not be used: 11 samples lacked sufficient volume for
testing by all systems, and status could not be resolved
for the remaining 8 samples. Of the 518 analyzable sam-
ples, the same 15 sera were IgM+ according to all three
assays, indicating the presence of an acute infection.
Two of the 15 IgM+ sera were also IgG– according to
the Merifluor assay, while 1 was IgG– and 3 were
borderline IgG+ according to the Enzygnost assay and 3
were IgG– according to the Novagnost assay. All of these
15 IgM+ assays were also EBNA-1–, confirming their
acute infection serostatus. Table 4 shows the final
assigned EBV serostatus for all 518 samples. Overall re-
sults for each assay type were compared to the assigned
EBV status and are displayed in Tables 5, 6, and 7. A
synopsis of assay agreement with EBV status is presented
in Table 8.
Enzygnost assay performance
In general, the Enzygnost assay results demonstrated
good total agreement with each of the three established
EBV status types: 100% for EBV-naive patients (95% CI:
90.97% to 100%), 100% for acute infection (95% CI:
78.2% to 100%), and 99.1% for past infection (95% CI:
97.81% to 99.75%).
Novagnost assay performance
Overall, Novagnost agreement with the established EBV
status for EBV-naive sera (89.7%, 95% CI = 75.78% to
97.13%) was somewhat lower than agreement using the
Enzygnost assays, but it was equally as good at detecting
acute infections (100%, 95% CI: 78.2% to 100%).
Interpreting remote (past) infection using the
Novagnost assay can be more challenging. Unlike the
Enzygnost and Merifluor assays which do not differenti-
ate between antibody types generated against total EBV
antigens, Novagnost specifically detects antibodies to
either VCA or EBNA-1 (depending on the assay), and
thus has the potential to report atypical/rare serotypes.
Additionally, approximately 5% of the population never
produces antibodies to EBNA-1 [7]. Thus, it could be
expected that approximately 5% of the group diagnosed
with acute infection were actually remotely infected,
which could affect the agreement for EBV acute infection
as well as past-infection status. This proved not to be the
case, however, as all patients in our study population with
the EBNA-1–lost serotype (isolated VCA IgG+) were VCA
IgM–, and thus were determined to have experienced a
past infection (although they are reported in Table 6 as
indeterminates). We analyzed the results from the
past-infection study population by both including and
excluding atypical, i.e., indeterminate, serotypes. When
all indeterminate serotypes were excluded, 98.8% of
samples correctly reported a remote infection (95% CI:
97.1% to 99.6%). If all serotypes were included, agree-
ment with the established EBV status was 86% (95%
CI: 82.5% to 89.02%). If only the samples that were
isolated–VCA IgG+ were presumed to reflect past
infections in which EBNA-1 IgG had been lost, how-
ever (see discussion below), then agreement with the
established EBV past-infection status rises to 97.6%;
and if both isolated–EBNA-1+ and isolated–VCA IgG+
serotypes are considered to reflect past infection,
agreement was as high as 99.6%.
Comparison to Merifluor assay performance
The Enzygnost and Novagnost assays were found to de-
tect acute infection, past infection, and EBV-naive status
at least as well as the Merifluor assays. The Merifluor
assay agreement for seronegativity (92.3%, 95% CI:
79.13% to 98.28%) was somewhat lower than that of the
Enzygnost assay (100%), but agreement for detecting
acute infection was identical for the Merifluor and
Enzygnost assays (100%, 95% CI: 78.2% to 100%).
Merifluor agreement to past infections was 98.1% (95%
CI: 96.35% to 99.11%), which was slightly lower than
Table 1 Serological assay interpretation per the
Enzygnost and Merifluor assays
anti-EBV IgM anti-EBV IgG Patient status
– – negativea
+ – Primary infection
+ + Primary infection
– + Past infection
aRetest in 7 days if suspicion remains high.
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agreement displayed by the Enzygnost assay, but greater
than agreement displayed by the Novagnost assay when
all serotypes were considered in the analysis. However,
Merifluor agreement to past infections was slightly lower
than the Novagnost assay past infection–agreement if in-
determinate serotypes were excluded from the Novagnost
analysis.
Discussion
We undertook this study to evaluate efficacy of the
Siemens Novagnost and Enzygnost EBV assays in routine
clinical use as an aid to determining EBV exposure and
serostatus. The samples were drawn as part of normal
clinical practice from patients presenting with symptoms
suspicious for EBV infection, or who had been exposed to a
person with a known EBV active infection. In our estima-
tion this study group was reasonably representative of pop-
ulations in industrialized nations at normal risk for EBV
infection [3], as 89.6% of our patient results demonstrated
previous exposure, 7.5% of the patients were determined to
be EBV naive, and only 2.9% were ultimately diagnosed
with an acute EBV infection.
For EBV serology to be a practical aid in the diagnosis
of IM (its most common clinical usage), it should either
rule in or rule out an acute infection with a high degree
of accuracy following a single blood draw. Additionally,
Table 2 Serological assay interpretation per the Novagnost assay
VCA IgM VCA IgG EBNA-1 Patient status Alternative interpretation
– – – Probably not infecteda
+ – – Primary early phase infection ● Possible cross-reactivity with primary CMV infection IgM
+ + – Primary acute infection
– + + Past infection
– + – Uncertain result ● Primary infection without VCA IgM
● Past infection with EBNA loss
– – + Uncertain result Very rare profile of past infection:
● Possible loss of VCA IgG
● Possible EBNA false positive
+ + + Uncertain result ● Just past primary infection
● Viral reactivation
● Cross-reaction with CMV primary infection IgM
● Nonspecific polyclonal IgM stimulation from a previous cross-reacting
● infectious agent
a Retest in 7 days.
Table 3 Serological assay interpretation per the Mikrogen assay
IgG strip IgM strip IgA Patient status
EBNA-1 p18 p23 BZLF1 EAs (p54, p138) p54 p138 ZEBRA p23
– – – – – – – – – – EBV negative
– – + or – + or – + or – + + or – + or – + or – Primary infection
– – + or – + or – + or – + or – + + or – + or –
– – + + weak + or - – – – – Past infection
– – + + weak + weak + weak + weak + weak + Secondary
reactivationa
+b + + + + – or weak + – or weak + – or weak + – or weak + EA + BZLF1+ VCA+ Reactivation




IgG/IgM/IgA: one isolated band (with the exception of the markers IgG EBNA-1 and IgG VCA) in only one antibody





a No clinical relevance.
b In a very few cases, loss of anti–EBNA-1 antibodies.
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it should also accurately distinguish primary acute infec-
tion from past infection, as well as identify those individ-
uals who are EBV naive, and who therefore remain at risk
of contracting an EBV infection. Ideally, results should not
be confounded by unusual serological profiles that require
additional testing to achieve resolution (e.g., isolated VCA
IgG, i.e., VCA IgM–/VCA IgG+/EBNA IgG–; isolated
EBNA, i.e., VCA IgM–/VCA IgG–/EBNA IgG+; or all
markers positive, i.e., VCA IgM+/VCA IgG+/EBNA IgG+).
Assays such as Enzygnost and Merifluor, which report
only qualitative results for total viral IgM and IgG, are less
subject to such confusion. Results from these two assays
demonstrated the greatest concordance with EBV-naive
status, and thus would be expected to perform reliably for
ruling out EBV infection. The Novagnost assay also
demonstrated good agreement with EBV-negative status,
although concordance was not as good as that achieved
by either the Enzygnost or Merifluor assays. This reduced
concordance is directly attributable to the larger number
of samples that were either incorrectly assigned or inde-
terminate (4 for Novagnost, versus 0 for Enzygnost and 3
for Merifluor). It is possible that we would have been able
to resolve the 4 indeterminate samples had we retested
these individuals 2 to 4 weeks later, following the manu-
facturer’s guidelines; this resolution might possibly have
improved the concordance for the Novagnost assay. How-
ever, since one of the stated purposes of our study was to
determine serostatus on the basis of a single blood draw,
only, we elected to not conduct later testing. It is import-
ant to note, however, that the manufacturer clearly states
that gray zones exist for the Novagnost assays (between
8.0 and 11.5 U) and the Enzygnost IgG assay (between 0.1
and 0.2 U), and recommends retesting patients with sera
yielding gray zone values two to four weeks after the
original blood draw. If samples continue to report in the
gray zone, they should be considered negative. Clinical
laboratories should keep this in mind and consider
retesting patients accordingly if alternative methods are
not available for resolving indeterminate samples.
All three of the assays demonstrated excellent and
identical concordance (100%) with the final EBV status
for sera from patients with an acute primary infection:
all three correctly identified those sera that were either
IgM+ only, or were IgM+ in the presence of either total
IgG or specific VCA IgG. Although it is not possible to
tell if the Enzygnost and Merifluor assays are detecting
EBNA-1 IgG as part of the IgG population, the absence
of EBNA-1 IgG detection by the Novagnost assay for all
15 acute sera confirms that none of the assays are
detecting EBNA-1 in these samples. This suggests that
both of the Siemens assays can be considered reliable for
detecting a primary acute EBV infection on the basis of
a single blood draw. Later retesting to establish a posi-
tive diagnosis of infectious mononucleosis is not likely
to be necessary unless phlebotomy has occurred so early
in the disease process that the patient has not yet devel-
oped a sufficient antibody response.
The greatest challenge in EBV testing can lie in differ-
entiating between an acute infection and a past infec-
tion, with or without reactivation. The Enzygnost assay
performed at least as well as the Merifluor assay in this
respect. The Enzygnost assay has also been shown to
perform well in other studies [13,14], although Bruu
et al. noted that because separate EBNA-1 detection is
lacking, it is not possible to determine if IgM positivity
is a true indication of primary acute infection, or if it
might represent reactivation in those cases where
EBNA-1 has been lost or was never generated [8,15].
Since reactivation is typically thought of as a rare event,
however, this is likely of little consequence for diagnosis
in the general population.
Atypical serotypes may be observed when using assays
such as Novagnost, as they detect EBNA-1 IgG specific-
ally, in addition to IgG to VCA; thus, their interpretation
can constitute a diagnostic challenge [9,16]. Garcia et al.
determined that the isolated EBNA-1 serotype occurred
in up to 50% of their patients ultimately diagnosed with
a latent EBV infection, and further noted that knowledge
of latent infection is especially critical preoperatively in
prospective solid organ transplant patients [17]. In a
study by Nystad et al., the simultaneous detection of
VCA IgM, VCA IgG and EBNA-1 was associated with
primary infection in 42% of their patients, although in at
least 23% of the study group it was associated with clin-
ically inconsequential EBV reactivation [18]. In contrast,
Table 4 Final EBV status for all 518 analyzable samples
Number Percent of population
Negative 39 7.5
Acute infection 15 2.9
Past infection 464 89.6
Table 5 Results using the Enzygnost assays as compared to established EBV status
Enzygnost interpretation
Negative Acute infection Past infection Indeterminate % agreement with EBV status
EBV status
Negative (N = 39) 39 0 0 0 100
Acute infection (N = 15) 0 15 0 0 100
Past infection (N = 464) 2 2 460 0 99.1
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Klutts et al. found that 77.8% of patients who were VCA
IgM+/VCA IgG+/EBNA-1+ proved to have had a past
infection, were recovering from a primary infection, or
were manifesting EBV reactivation [9]. Debyser et al.
also associated the triple-positive serotype with reactiva-
tion, noting that reactivation can also be indicated by
the VCA IgM+/VCA IgG–/EBNA-1+ serotype, but
proposed that reactivation is only relevant in patients
suffering from (or as in the case with Garcia et al., [17]
subject to) immune suppression. Additionally, they
suggested that isolated VCA IgG, especially when the
IgG titer is high, was indicative of persistent or chronic
EBV infection [19]; however, 69.6% of patients with the
VCA IgG+ only serotype in the study by Klutts et al. [9]
were diagnosed with a past infection.
In our opinion, the isolated VCA IgG+ results gener-
ated by the Novagnost assay are the most problematic
when screening otherwise presumed healthy individuals.
Although, as Klutts suggests, the majority of these likely
represent remote infections, it is not possible to tell
from the assay results alone if some of these sera might
be indicative of a late active infection with early IgM
decline and weak EBNA response, or a remote infection
in which EBNA IgG has been lost or never generated.
Since there is the possibility that individuals with
isolated VCA IgG+ could have an acute infection, sera
such as these should be tested for VCA IgG avidity or
their status should be confirmed by some other method,
such as Western blot or PCR [20-22]. Since the goal of
our study was to evaluate only the performance of the
microtiter assays as they compared to each other, we did
not conduct any further evaluation of any of the indeter-
minate sera. While this might be considered a limitation
of the study, we felt that further testing was not
warranted as the original testing indicated 100% con-
cordance between the three methods for detecting acute
infection, and in all likelihood, the indeterminate sera
truly represented remote infections.
Despite the difficulties that EBNA IgG detection can
cause in interpreting rare serotypes, it is still considered
to be a valuable component of EBV testing; absence of
EBNA IgG in the presence of VCA IgM is considered
definitive for ruling in acute infection, while the pres-
ence of EBNA IgG typically rules out acute infection,
even if VCA IgM antibodies persist. Although, as shown
by Nystad and Klutts in the above discussion, EBNA-1
can be indicative of a resolving infection. VCA IgG posi-
tivity, however, can be equally attributable to acute,





















Negativea (N = 39) 35 1 1 0 0 0 89.7
Acute infection (N = 15) 0 15 0 0 0 0 100%





a Determination could not be made for 2 sera which did not match any of the indeterminate types listed in the table.
b Agreement if all indeterminate results are included in the analysis.
c Agreement if all indeterminate results are excluded from the analysis (i.e., 399/404).
d Agreement if all isolated EBNA-1 results are assumed to represent past infections.
e Agreement if results are considered indeterminate because they are VCA IgG+–only (isolated VCA IgG) are instead considered positive, and thus also most likely
represent past infections.
f Agreement if all isolated EBNA-1 and all isolated VCA IgG+ results are assumed to represent past infections.
Table 7 Results using the Merifluor assays as compared to established EBV status
Merifluor interpretation
Negative Acute infection Past infection Indeterminate % agreement with EBV status
EBV status
Negative (N = 39) 36 1 2 0 92.3
Acute infection (N = 15) 0 15 0 0 100
Past infection (N = 464) 1 5 455 3 98.1
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resolving, or remote infections. Furthermore, VCA IgG
levels may fall to undetectable levels in some individuals
following acute infection, while EBNA IgG generally
persists for life [23].
In our hands, the Novagnost assay performed about as
well as both the Enzygnost and Merifluor assays for
detecting active primary infection, but because the
Novagnost assay reports the presence of antibodies to
EBNA-1 in addition to the VCA antibodies, it was more
difficult to appropriately classify all past infections. Of
the total 464 sera determined to represent past infec-
tions, 65 expressed atypical serotypes and were subse-
quently classified as indeterminate. However, the 55
samples demonstrating isolated VCA IgG+ status consti-
tute approximately 12% of the study population, which
is consistent with the expected percentage of individuals
who either never develop EBNA-1 antibodies or in
whom antibody production is lost. Since VCA IgM
rarely persists beyond acute infection, it is likely that
these 55 samples do, indeed, represent patients with
remote exposure to EBV, although it cannot be deter-
mined if these sera represent reactivation or chronic
infection. Additionally, eight samples were positive only
for EBNA-1 IgG, while two samples were positive for all
markers; either of these profiles could be interpreted as
past infection as shown in Table 2, and by the arguments
presented by other researchers cited in the previous
paragraphs.
Conclusion
Overall, we found that both the Siemens Enzygnost and
Novagnost EBV assays demonstrated very good agree-
ment with assigned serostatus. Additionally, the ease
with which these two assays may be used makes them
well suited for laboratory assessment of infectious
mononucleosis caused by primary EBV infection. Both
assays can be automated and generate the same quality
of results as manual assays, but require minimal hands-on
involvement; this is a clear advantage in a busy, high-
volume laboratory. Furthermore, because the Enzygnost
assay requires reagents for detection of only two anti-
bodies, it offers a considerable cost savings. Despite the
potential for indeterminate results using the Novagnost
assay, we found the test of practical use, especially consid-
ering the time-saving convenience of its ready-to-use
reagents and their long stability.
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Table 8 Overall agreement of sample results for the Enzygnost, Novagnost, and Merifluor assays with the established
EBV status, including 95% confidence intervals (95% CI)
% agreement with established EBV status
Negative (N = 39) Acute infection (N = 15) Past infection (N = 464)
[95% CI] [95% CI] [95% CI]
Enzygnost 100 100 99.1
[90.97% – 100%] [78.2% – 100%] [97.81% – 99.75%]
Novagnost 89.7 100 86a, 98.8b
[75.78% – 97.13%] [78.2% – 100%] [82.5% – 89.02%]a, [97.1% to 99.6%]b
Merifluor IFA 92.3 100 98.1
[79.13% – 98.38%] [78.2% – 100%] [96.35% – 99.11%]
a Agreement if all indeterminate results are included in the analysis.
b Agreement if all indeterminate results are excluded from the analysis.
Kreuzer et al. BMC Infectious Diseases 2013, 13:260 Page 8 of 9
http://www.biomedcentral.com/1471-2334/13/260
References
1. World Health Organization: Initiative for Vaccine Research (IVR): Viral Cancers;
EBV. 2011. http://www.who.int/vaccine_research/diseases/viral_cancers/en/
index1.html.
2. Luzuriaga K, Sullivan JL: Infectious mononucleosis. NEJM 2010,
362(21):1993–2000.
3. Ebell MH: Epstein–Barr Virus Infectious Mononucleosis. Am Fam Phys
2004, 70(7):1279–1287.
4. Hurt C, Tammaro D: Diagnostic Evaluation of Mononucleosis-Like
Illnesses. Am J Med 2007, 120(911):e1–e8.
5. Infectious Mononucleosis Slide Test. In ARUP’s Guide to Clinical
Laboratory Testing. 3rd edition. Edited by Weiss RL. Utah: ARUP
Laboratories; 2001:424–425.
6. Monospot Screen (Heterophil Screen)—Blood. In Laboratory Tests and
Diagnostics Procedures. 5th edition. Edited by Chernecky CC, Berger BJ.
Missouri: Saunders Elsevier; 2008:789–80.
7. Rea TD, Ashley RL, Russo JE, Buchwald DS: A Systematic Study of Epstein–
Barr Virus Serologic Assays Following Acute Infection. Am J Clin Pathol
2002, 117:156–161.
8. Tselis A, Merline JR, Storch GA: Epstein–Barr Virus Disease—Serologic and
Virologic Diagnosis. In Epstein–Barr Virus. Edited by Tselis A, Jenson HB.
New York and London: Taylor & Francis Group; 2006:126–146.
9. Klutts JS, Ford BA, Perez NR, Gronowski AM: Evidence-based approach for
interpretation of Epstein–Barr virus serological patterns. J Clin Microbiol
2009, 47(10):3204–3210.
10. Martins TB, Litwin CM, Hill HR: Evaluation of a multiplex fluorescent
microsphere immunoassay for the determination of Epstein–Barr virus
serologic status. Am J Clin Pathol 2008, 129(1):34–41.
11. De Paschale M, Agrappi C, Manco MT, Mirri P, Viganò EF, Clerici P:
Seroepidemiology of EBV and Interpretation of the “Isolated VCA IgG”
Pattern. J Med Virol 2009, 81:325–331.
12. Guidance for Industry and FDA Staff: Statistical Guidance on Reporting Results
from Studies Evaluating Diagnostic Tests, U.S. Department of Health and
Human Services Food and Drug Administration Center for Devices and
Radiological Health. Diagnostic Devices Branch, Division of Biostatistics.
Office of Surveillance and Biometrics. 2007. http://www.fda.gov/downloads/
MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/
ucm071287.pdf.
13. Gutiérrez J, Vergara MJ, Piédrola G, Maroto MC: Clinical reliability of IgG,
IgA, and IgM antibodies in detecting Epstein–Barr virus at different
stages of infection with a commercial nonrecombinant polyantigenic
ELISA. J Clin Lab Anal 1999, 13(2):65–68.
14. Kleines M, Scheithauer S, Ritter K, Häusler M: Sensitivity of the
Enzygnost anti-EBV/IgG for the determination of the Epstein–Barr
virus immune status in pediatric patients. Diagn Microbiol Infect Dis 2006,
55(3):247–249.
15. Bruu AL, Hjetland R, Holter E, Mortensen L, Natås O, Petterson W, et al:
Evaluation of 12 commercial tests for detection of Epstein–Barr virus-
specific and heterophile antibodies. Clin Diagn Lab Immunol 2000,
7(3):451–456.
16. Gärtner BC, Fischinger JM, Roemer K, Mak M, Fleurent B, Mueller-Lantzsch N:
Evaluation of a recombinant line blot for diagnosis of Epstein–Barr Virus
compared with ELISA, using immunofluorescence as reference method.
J Virol Methods 2001, 93(1–2):89–96.
17. García T, Tormo N, Gimeno C, Navarro D: Assessment of Epstein–Barr
virus (EBV) serostatus by enzyme immunoassays: plausibility of the
isolated EBNA-1 IgG positive serological profile. J Infect 2008,
57(4):351–353.
18. Nystad TW, Myrmel H: Prevalence of primary versus reactivated
Epstein–Barr virus infection in patients with VCA IgG-, VCA IgM- and
EBNA-1-antibodies and suspected infectious mononucleosis. J Clin
Virol 2007, 38(4):292–297.
19. Debyser Z, Reynders M, Goubau P, Desmyter J: Comparative evaluation of
three ELISA techniques and an indirect immunofluorescence assay for
the serological diagnosis of Epstein–Barr virus infection. Clin Diagn Virol
1997, 8(1):71–81.
20. Weissbrich B: The Use of Semi-Automated EBV IgG Avidity
Determination for the Diagnosis of Infectious Mononucleosis. J Med
Virol 1998, 54:145–153.
21. Hess RD: Routine Epstein–Barr Virus Diagnostics from the Laboratory
Perspective: Still Challenging after 35 Years. J Clin Microbiol 2004,
42(8):3381–3387.
22. De Paschale M, Clerici P: Serological diagnosis of Epstein–Barr virus
infection: Problems and solutions. World J Virol 2012, 1(1):31–43.
23. Epstein–Barr Virus and Infectious Mononucleosis, Center for Disease Control,
National Center for Infectious Diseases. http://www.cdc.gov/ncidod/
diseases/ebv.htm.
doi:10.1186/1471-2334-13-260
Cite this article as: Kreuzer et al.: Reliability of the Siemens Enzygnost
and Novagnost Epstein–Barr Virus assays for routine laboratory
diagnosis: agreement with clinical diagnosis and comparison with the
Merifluor Epstein–Barr Virus immunofluorescence assay. BMC Infectious
Diseases 2013 13:260.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kreuzer et al. BMC Infectious Diseases 2013, 13:260 Page 9 of 9
http://www.biomedcentral.com/1471-2334/13/260
